Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile TP53 P72R
Therapy Cyclophosphamide + Fluorouracil + Pirarubicin
Indication/Tumor Type breast cancer
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
TP53 P72R breast cancer predicted - sensitive Cyclophosphamide + Fluorouracil + Pirarubicin Phase I Actionable In a Phase I trial, breast cancer patients harboring TP53 P72R were reported to have a better response to anthracycline-based neoadjuvant therapies, including pirarubicin in combination with Cytoxan (cyclophosphamide) and Adrucil (fluorouracil) (PMID: 16243804). 16243804
PubMed Id Reference Title Details
(16243804) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Full reference...